Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $29.50 Average Price Target from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.50.

A number of research analysts have recently commented on the company. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. HC Wainwright increased their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, August 12th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Insider Activity

In related news, insider Carmen Jeffrey Del sold 36,058 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the transaction, the insider now owns 12,369 shares of the company’s stock, valued at $227,836.98. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares in the company, valued at $7,012,367.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 201,058 shares of company stock valued at $4,018,188. Insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after buying an additional 263,099 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after acquiring an additional 2,965,310 shares during the period. Janus Henderson Group PLC grew its holdings in Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after acquiring an additional 1,587,794 shares during the period. Finally, Renaissance Technologies LLC raised its position in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after acquiring an additional 287,300 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:CPRX opened at $19.56 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $11.55 and a fifty-two week high of $21.67. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of 36.22, a price-to-earnings-growth ratio of 3.27 and a beta of 0.75. The firm’s 50 day moving average price is $19.22 and its 200 day moving average price is $16.95.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.13. The business had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. On average, equities analysts anticipate that Catalyst Pharmaceuticals will post 1.82 EPS for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.